A research team has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell ...

The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, ...

The trial (NCT04214288) included 240 patients with advanced, ER-positive, HER2-negative breast cancer ... were similar. Overall survival data were not mature at the data cutoff. The median overall ...

Experts have highlighted seven key symptoms of a disease with a notoriously low survival ... pancreatic cancer primarily to its late discovery, as the disease is usually quite advanced when ...

to launch a PLUS e-Center to bridge remote work opportunities for breast cancer survivors and their families. With access to roles as online tutors and virtual assistants, “Pink Warriors ...

TL;DR: SK hynix VP Lee Kang-wook emphasized at Semicon Korea 2024 that advanced packaging is crucial ... product value to determining company survival. He highlighted that packaging requires ...

locally advanced breast cancer and metastatic breast cancer (mBC). While aBC/mBC remains largely incurable, important advances over the past 20 years have improved overall survival in patients with ...

Talazoparib is a PARP inhibitor, a drug that stops damaged cancer cells from repairing themselves. “Having a novel combination of well-tolerated medications significantly improving overall survival ...

In MBC, Kisqali has consistently demonstrated statistically significant overall survival benefit ... menopausal patients with HR+/HER2- advanced breast cancer. Further, Kisqali in combination with ...

In MBC, Kisqali has consistently demonstrated statistically significant overall survival benefit ... menopausal patients with HR+/HER2- advanced breast cancer. Further, Kisqali in combination with ...